Vertex Pharmaceuticals Management
Management Kriterienprüfungen 3/4
Vertex Pharmaceuticals CEO ist Reshma Kewalramani , ernannt in Apr 2020, hat eine Amtszeit von 6.25 Jahren. Die jährliche Gesamtvergütung beträgt $21.14M , bestehend aus 7.6% Gehalt und 92.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.039% der Aktien des Unternehmens, im Wert von $48.98M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.5 Jahre bzw. 6.9 Jahre.
Wichtige Informationen
Reshma Kewalramani
Geschäftsführender
US$21.1m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 7.57% |
| Amtszeit als Geschäftsführer | 6.3yrs |
| Eigentum des Geschäftsführers | 0.04% |
| Durchschnittliche Amtszeit des Managements | 6.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6.9yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • Jul 08
VRTX: Rich Crinetics Deal Will Weigh On Future Risk Reward Profile
Vertex Pharmaceuticals' fair value estimate has been adjusted higher by about $9.69 to $423.75 as analysts factor in updated assumptions on revenue growth, margins, and future P/E following the Crinetics acquisition and a series of upward price target revisions, including recent moves to $570 at RBC Capital and $350 at Baird. Analyst Commentary Recent research on Vertex Pharmaceuticals clusters around the planned Crinetics acquisition and how it reshapes the company’s pipeline mix, capital deployment, and earnings profile.Seeking Alpha • Jun 30
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
Summary Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driving highly predictable, recurring revenue and justifying its valuation premium. VRTX is leveraging its CF cash flows to expand into pain, hematology, and renal franchises, with promising catalysts in each area, notably Pove for IgAN. Non-CF franchises are gaining traction, with Journavx and Casgevy contributing to revenue growth; renal (Pove) is positioned to become a major driver post-2027. I maintain a Buy rating on VRTX, citing its wide moat, robust pipeline, pristine balance sheet, and clear sightlines to long-term market-beating returns. Read the full article on Seeking Alpha
Narrativ-Update • Jun 17
VRTX: Kidney Franchise And Pipeline Expansion Will Drive Future Stock Upside
Vertex Pharmaceuticals' latest narrative update reflects a modest recalibration in analyst price targets, with figures such as Truist's move to $542 and Wells Fargo's lift to $550 framed around analysts' view that the emerging kidney franchise can grow into blockbuster assets and broaden the company's portfolio. Analyst Commentary Recent Street research on Vertex Pharmaceuticals highlights a generally constructive tone, with bullish analysts pointing to the expanding kidney franchise and a series of upward price target revisions as key supports for the stock's valuation and growth narrative.Narrativ-Update • Jun 03
VRTX: Kidney Franchise Progress Will Drive Future Upside Beyond CF
Analysts have nudged their average price target on Vertex Pharmaceuticals higher by a few dollars to around the mid $500s to low $600s, citing positive Phase 3 RAINIER data and the perceived de-risking of the emerging kidney franchise as key reasons for the change. Analyst Commentary Bullish analysts are broadly aligning around a more constructive view on Vertex Pharmaceuticals following the RAINIER readout, with several pointing to the kidney franchise as a key driver for the stock story alongside the established cystic fibrosis business.Narrativ-Update • May 19
VRTX: CF Franchise And Nephrology Pipeline Will Shape Balanced Future Risk Profile
Analysts have inched their fair value target for Vertex Pharmaceuticals higher to about $414 per share. This reflects updated assumptions that pair slightly more conservative revenue growth expectations with higher projected profit margins and a lower anticipated future P/E multiple.Narrativ-Update • May 05
VRTX: CF Base And Nephrology Expansion Will Define Balanced Future Risk Profile
Analysts have inched their average price target for Vertex Pharmaceuticals higher by a few dollars, citing stronger confidence in povetacicept after positive Phase 3 RAINIER data in IgA nephropathy and a broader nephrology pipeline thesis, while keeping valuation assumptions such as P/E and discount rate broadly consistent. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has centered on povetacicept and the nephrology pipeline, with several major firms adjusting their models after the Phase 3 RAINIER interim readout in IgA nephropathy and following Q4 results.Narrativ-Update • Apr 20
VRTX: CF Franchise And Kidney Pipeline Will Shape Balanced Risk Profile
Vertex Pharmaceuticals' fair value estimate has shifted from $403.80 to $412.49 as analysts refresh models following multiple price target increases tied to positive Phase 3 povetacicept data and a reassessment of the company's nephrology pipeline potential. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has leaned constructive overall, with several firms lifting price targets following the Phase 3 RAINIER interim readout for povetacicept and updating models around the nephrology pipeline.Narrativ-Update • Apr 05
VRTX: Renal Franchise Progress And CF Leadership Will Drive Future Upside
Vertex Pharmaceuticals' analyst fair value estimate has shifted to $641 from $604. This reflects analysts' updated views on the company's diversified pipeline following positive Phase 3 povetacicept data in IgA nephropathy and a series of higher Street price targets.
Narrativ-Update • Mar 22
VRTX: Renal Trial Success And Nephrology Pipeline Will Drive Next Phase
Vertex Pharmaceuticals' analyst fair value estimate has moved from $504.04 to $547.72. Analysts point to higher modeled revenue growth, slightly stronger profit margins, a richer future P/E assumption, and a wave of Street price target hikes tied to positive povetacicept Phase 3 RAINIER data and the growing nephrology pipeline.Narrativ-Update • Mar 06
VRTX: CF Dependence Will Heighten Risk Around Upcoming Renal Readouts
Analysts have nudged their target on Vertex Pharmaceuticals higher, with our fair value estimate moving from $401.30 to $403.80. This reflects updated Q4 results, slightly adjusted revenue growth and margin assumptions, and ongoing confidence in the broader pipeline, as seen in a series of recent price target increases across the Street.Narrativ-Update • Feb 20
VRTX: CF Reliance Will Expose Renal Pipeline Execution Risks
Vertex Pharmaceuticals' updated analyst price target reflects an increase of $23.78 to $401.30, as analysts incorporate refreshed Q4 outcomes, pipeline commentary on programs like povetacicept and IgAN, and modest adjustments to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Street research around Vertex Pharmaceuticals has been active following the latest Q4 update, with several firms revisiting their models, refreshing pipeline assumptions, and revising price targets.Narrativ-Update • Feb 06
VRTX: CF Dependence And Pipeline Execution Risks Will Test Bullish Repricing
Analysts have raised their fair value estimate for Vertex Pharmaceuticals by about US$33 to approximately US$378, citing a series of recent rating upgrades and higher price targets linked to its cystic fibrosis franchise and late-stage pipeline potential. Analyst Commentary Recent research on Vertex Pharmaceuticals has been dominated by upgrades and higher price targets, with several firms shifting to more positive ratings and highlighting the cystic fibrosis portfolio and late stage pipeline as key supports for the updated fair value assessments.Narrativ-Update • Jan 23
VRTX: CF Cash Flows And Renal Data Will Shape Balanced Next Phase
Analysts have nudged their fair value estimate for Vertex Pharmaceuticals higher to about $504, citing a slightly richer assumed future P/E multiple and modestly stronger revenue growth expectations, even as they factor in a lower profit margin and a slightly higher discount rate. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has turned more constructive, with several firms shifting to more positive ratings and setting price targets above the current fair value estimate.Narrativ-Update • Jan 09
VRTX: CF Durability And Kidney Pipeline Data Will Define Next Phase
Analysts have lifted their Vertex Pharmaceuticals fair value estimate by about US$11 to US$496.16, reflecting updated assumptions on revenue growth, margins and future P/E, as recent research highlights confidence in the durability of its cystic fibrosis franchise and potential upside from its broader pipeline. Analyst Commentary Recent Street research around Vertex Pharmaceuticals points to a generally constructive view, with most commentary focusing on the durability of the cystic fibrosis franchise, the breadth of the pipeline and how these factors feed into valuation targets and rating changes.Narrativ-Update • Dec 18
VRTX: Cystic Fibrosis And Gene Editing Advances Will Drive Upside Potential
Narrative Update The analyst price target for Vertex Pharmaceuticals has been modestly reduced to about $604 from roughly $616 as analysts factor in a slightly higher discount rate and marginally slower revenue growth, partially offset by improved profitability and a lower assumed future P/E multiple. Analyst Commentary Bullish analysts remain broadly constructive on Vertex Pharmaceuticals, emphasizing durable execution in cystic fibrosis, a deep late stage pipeline, and multiple emerging revenue drivers that, in their view, support premium valuation multiples despite modest target tweaks.Narrativ-Update • Dec 04
VRTX: Kidney Pipeline And Gene Editing Will Shape Next Phase
The analyst price target for Vertex Pharmaceuticals has been nudged higher to about $485 from roughly $480 as analysts point to a healthier long term earnings profile supported by ongoing strength in the cystic fibrosis franchise, measured diversification investments, and an increasingly innovation focused large cap biopharma setup. Analyst Commentary Recent research updates on Vertex Pharmaceuticals highlight a broadly constructive stance on the name, with most price target changes and rating initiations reinforcing confidence in the company’s growth algorithm and innovation pipeline, even as some voices flag valuation and execution constraints as the franchise matures.Analyseartikel • Nov 11
Vertex Pharmaceuticals' (NASDAQ:VRTX) Performance Is Even Better Than Its Earnings Suggest
Even though Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) recent earnings release was robust, the market didn't...Analyseartikel • Sep 19
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-sales (or "P/S") ratio of...Narrativ-Update • Sep 04
Gene Editing And New Therapies Will Transform Global Healthcare
Analysts maintain a cautious-but-constructive stance on Vertex Pharmaceuticals, citing strong CF performance and resilient topline results offset by pipeline setbacks and future revenue concentration risks, with the consensus price target unchanged at $481.04. Analyst Commentary Bullish analysts highlight Vertex’s continued strong execution track record, robust base cystic fibrosis (CF) business, solid Q2 results with topline beats, and a positive long-term growth outlook beyond near-term setbacks.Neues Narrativ • Apr 08
New ALYFTREK And JOURNAVX Will Expand Patient Access
Vertex is set to drive revenue growth by expanding its drug portfolio, notably with ALYFTREK and JOURNAVX, targeting new patient demographics.Seeking Alpha • Apr 06
Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Summary Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine (Journavx) shows promise as a non-addictive pain treatment, offering systemic relief without opioid-related side effects, but faces Tier 3 insurance hurdles. Financially strong with a market cap of $124bn and $11.2bn in cash, Vertex's pain program needs further trials to overcome high placebo effects in Lumbosacral Radiculopathy. While Vertex's diversification is commendable, investors should wait for a few quarters of revenue from the pain program before making investment decisions. Read the full article on Seeking AlphaSeeking Alpha • Mar 06
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Summary Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company’s 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs. Despite potential headwinds, Vertex's strong cash position and promising pipeline support a “Buy” rating for VRTX stock, with expectations of further long-term growth and multiple blockbuster drugs. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Summary JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. With multiple ongoing clinical trials and a robust pipeline, Vertex is poised to exceed conservative analyst revenue projections, making the stock a STRONG BUY with a 12-month price of $550/share. Read the full article on Seeking AlphaSeeking Alpha • Jan 14
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
Summary I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is under investigation as a pain relief medication. In that earlier post on this drug, it had shown some very interesting (though modest) activity in post-surgical patients, albeit with some questions about its efficacy relative to Vicodin standard-of-care. Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain. Just before the holiday break, Vertex reported on another of these trials with suzetrigine in sciatica patients. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Summary Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the cystic fibrosis (CF) drug market, including recent FDA approval for Alyftrek, ensures strong revenue and market expansion. The company's pipeline diversification, targeting diabetic peripheral neuropathy, IgA nephropathy, type 1 diabetes, and gene editing, promises long-term growth. Despite high valuation risks, VRTX's innovative CF treatments and diversified pipeline make it a compelling long-term investment opportunity. Read the full article on Seeking AlphaAnalyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$21m | US$2m | US$4b |
| Sep 30 2025 | n/a | n/a | US$4b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | -US$989m |
| Dec 31 2024 | US$22m | US$2m | -US$536m |
| Sep 30 2024 | n/a | n/a | -US$480m |
| Jun 30 2024 | n/a | n/a | -US$490m |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$16m | US$1m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$9m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$702k | US$1b |
Vergütung im Vergleich zum Markt: ReshmaDie Gesamtvergütung ($USD21.14M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD14.71M).
Entschädigung vs. Einkommen: ReshmaDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Reshma Kewalramani (53 yo)
6.3yrs
Amtszeit
US$21,144,261
Vergütung
Dr. Reshma Kewalramani, M.D., FASN, was Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 17yrs | keine Daten | 0.014% $ 17.6m | |
| CEO, President & Director | 6.3yrs | US$21.14m | 0.039% $ 49.0m | |
| Executive VP | 7.3yrs | US$8.24m | 0.011% $ 13.8m | |
| Executive VP & Chief Patient and External Affairs Officer | 19yrs | US$6.78m | 0.026% $ 32.8m | |
| Executive VP and Chief Regulatory & Quality Officer | 8.8yrs | US$6.97m | 0.018% $ 22.6m | |
| Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | 6.8yrs | US$6.65m | 0.0060% $ 7.6m | |
| Senior VP & Chief Accounting Officer | 5.2yrs | keine Daten | 0.0026% $ 3.3m | |
| Executive VP & Chief Scientific Officer | less than a year | keine Daten | 0.0029% $ 3.6m | |
| Senior Vice President of Investor Relations | 3.8yrs | keine Daten | keine Daten | |
| EVP, Chief Legal Officer & Corporate Secretary | less than a year | keine Daten | 0.0075% $ 9.5m | |
| Senior VP & Chief Communications Officer | 7.5yrs | keine Daten | keine Daten | |
| Senior VP & Chief Human Resources Officer | 8.9yrs | keine Daten | keine Daten |
6.5yrs
Durchschnittliche Betriebszugehörigkeit
57yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von VRTX ist erfahren und erfahren (durchschnittliche Amtszeit von 6.5 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 17yrs | keine Daten | 0.014% $ 17.6m | |
| CEO, President & Director | 6.4yrs | US$21.14m | 0.039% $ 49.0m | |
| Lead Independent Director | 28.5yrs | US$615.13k | 0.018% $ 22.4m | |
| Independent Director | 9.1yrs | US$545.25k | 0.0027% $ 3.4m | |
| Independent Director | 7.4yrs | US$565.36k | 0.0022% $ 2.7m | |
| Independent Director | 11.1yrs | US$560.36k | 0.0016% $ 2.0m | |
| Independent Director | 2.8yrs | US$540.13k | 0.00045% $ 569.3k | |
| Independent Director | 6.1yrs | US$552.86k | 0.00065% $ 822.3k | |
| Independent Director | 2.6yrs | US$528.25k | 0.00064% $ 809.6k | |
| Independent Director | 2.2yrs | US$537.86k | 0.00036% $ 455.4k |
6.9yrs
Durchschnittliche Betriebszugehörigkeit
62.5yo
Durchschnittliches Alter
Erfahrener Vorstand: VRTXDie Vorstandsmitglieder gelten als erfahren (6.9 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/09 13:46 |
| Aktienkurs zum Tagesende | 2026/07/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Vertex Pharmaceuticals Incorporated wird von 58 Analysten beobachtet. 29 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Eliana Merle | Barclays |